Jiangxi Fushine Pharmaceutical Co Ltd (300497) — Tangible Net Worth Ratio
Jiangxi Fushine Pharmaceutical Co Ltd (300497) has a Tangible Net Worth Ratio of 87.4% as of March 2026. This metric is calculated by deducting intangible assets (CN¥285.64 Million) from net assets (CN¥2.27 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Jiangxi Fushine Pharmaceutical Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Jiangxi Fushine Pharmaceutical Co Ltd Tangible Net Worth Ratio (2011–2025)
This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 87.4%, reflecting net assets of CN¥2.27 Billion with intangible assets of CN¥285.64 Million CNY. See 300497 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market value of Jiangxi Fushine Pharmaceutical Co Ltd.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 86.9% | CN¥2.20 Billion | CN¥287.85 Million | CN¥4.40 Billion | ▼ -2.3 pp |
| 2024 | 89.2% | CN¥2.18 Billion | CN¥235.00 Million | CN¥4.54 Billion | ▼ -1.0 pp |
| 2023 | 90.2% | CN¥2.47 Billion | CN¥241.07 Million | CN¥4.82 Billion | ▼ -0.5 pp |
| 2022 | 90.7% | CN¥2.69 Billion | CN¥249.71 Million | CN¥5.06 Billion | ▼ -0.5 pp |
| 2021 | 91.2% | CN¥2.91 Billion | CN¥256.32 Million | CN¥4.68 Billion | ▼ -0.7 pp |
| 2020 | 91.9% | CN¥3.05 Billion | CN¥246.28 Million | CN¥4.05 Billion | ▼ -0.5 pp |
| 2019 | 92.4% | CN¥1.53 Billion | CN¥116.51 Million | CN¥2.60 Billion | ▲ +1.3 pp |
| 2018 | 91.1% | CN¥1.15 Billion | CN¥102.58 Million | CN¥2.20 Billion | ▲ +2.2 pp |
| 2017 | 88.9% | CN¥966.71 Million | CN¥107.75 Million | CN¥1.79 Billion | ▼ -0.5 pp |
| 2016 | 89.3% | CN¥784.17 Million | CN¥83.80 Million | CN¥1.40 Billion | ▼ -0.5 pp |
| 2015 | 89.8% | CN¥596.21 Million | CN¥60.85 Million | CN¥1.01 Billion | ▲ +11.6 pp |
| 2014 | 78.2% | CN¥283.26 Million | CN¥61.87 Million | CN¥632.35 Million | ▲ +5.7 pp |
| 2013 | 72.5% | CN¥229.76 Million | CN¥63.27 Million | CN¥541.31 Million | ▲ +7.5 pp |
| 2012 | 65.0% | CN¥184.60 Million | CN¥64.62 Million | CN¥476.31 Million | ▲ +16.2 pp |
| 2011 | 48.8% | CN¥120.52 Million | CN¥61.67 Million | CN¥352.57 Million | — |